Three US states are attempting to intervene in a lawsuit that seeks to roll back changes the Food and Drug Administration made to the abortion pill mifepristone’s Risk Evaluation and Mitigation Strategy, a move that puts the entire agency’s drug approval process – and the pharmaceutical industry that relies upon the certainty of the status quo – in jeopardy, again.
Déjà Vu: Revived Mifepristone Case Puts FDA And Pharma At Risk Again
The outcome of the November presidential election may impact whether the government is willing to defend FDA's relaxation of the mifepristone REMS. The case poses risks for the broader drug approval process.
More from Litigation
More from Legislation
• By
Trial sponsors in Germany should start preparing negotiation strategies to tackle difficult discussions with trial sites over standardized clauses.
• By
Newly proposed legislation for bolstering the EU’s drug manufacturing capacity and reducing its overreliance on foreign manufacturers includes a number of measures, such a requirement for EU countries to prioritize the security of supply over price when procuring drugs.
• By
An enhanced role for patients in the European Medicines Agency was a key proposal within the EU pharmaceutical legislation overhaul – but patient groups warn this provision could be scrapped or weakened due to ongoing negotiations.